Main Menu

Diverse human cancers like colorectal, pancreatic, ovarian, melanoma, and pre-cancers express NADPH oxidases (NOX) at high levels. Reactive oxygen species (ROS) produced from metabolic reactions catalyzed by NOX in tumors are essential to the tumor’s growth. Though drugs that inhibit ROS production by NOX could be effective against a variety of human cancers, these types of drugs are not widely available.

Summary: 
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways.

Summary: 

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 

Description of Technology: 

Value Proposition

Summary: 

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.

Summary

The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.

Summary: 
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.

Summary: 
Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.

Description of Technology: 
Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.

This technology includes the creation and use of A3 adenosine receptor (A3AR)-selective agonists for treating chemotherapy-induced peripheral neuropathy, chronic neuropathic pain, rheumatoid arthritis, psoriasis, and other conditions. A3 receptors for adenosine are found in most cells and endogenous activation of the A3 receptors can result in apoptosis, thereby relieving the inflammation or targeting a tumor. A3AR agonists have been a promising strategy for the treatment of various diseases.

This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide halts the membrane-fusion step, creating a one-two punch against viral entry.